RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Pipeline Review, H2 2018
RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Pipeline Review, H2 2018
SUMMARY
According to the recently published report 'RAC Alpha SerineThreonine Protein Kinase - Pipeline Review, H2 2018'; RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) pipeline Target constitutes close to 13 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes.
RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - RAC-alpha serine/threonine-protein kinase is an enzyme encoded by the AKT1 gene. It regulates many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine or threonine phosphorylation of a range of downstream substrates. It regulates the storage of glucose in the form of glycogen by phosphorylating GSK3A and GSK3B resulting in inhibition of its kinase activity.
It act as key modulator of the AKT-mTOR signaling pathway controlling the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. Signals downstream of phosphatidylinositol 3-kinase to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor I (IGF-I).
The report 'RAC Alpha SerineThreonine Protein Kinase - Pipeline Review, H2 2018' outlays comprehensive information on the RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 6, 2 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.
Report covers products from therapy areas Oncology, Hematological Disorders, Non Malignant Disorders and Other Diseases which include indications Endometrial Cancer, Metastatic Breast Cancer, Melanoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer, Hepatocellular Carcinoma, Prostate Cancer, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Small-Cell Lung Cancer, Solid Tumor, Anal Cancer, Fallopian Tube Cancer, Gastric Cancer, Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), Lymphoma, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Orphan Diseases (Rare Diseases), Pancreatic Cancer, Peritoneal Cancer, Proteus Syndrome, Renal Cell Carcinoma, Salivary Gland Cancer, Sickle Cell Disease and Thymoma (Thymic Epithelial Tumor).
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'RAC Alpha SerineThreonine Protein Kinase - Pipeline Review, H2 2018'; RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) pipeline Target constitutes close to 13 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes.
RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - RAC-alpha serine/threonine-protein kinase is an enzyme encoded by the AKT1 gene. It regulates many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine or threonine phosphorylation of a range of downstream substrates. It regulates the storage of glucose in the form of glycogen by phosphorylating GSK3A and GSK3B resulting in inhibition of its kinase activity.
It act as key modulator of the AKT-mTOR signaling pathway controlling the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. Signals downstream of phosphatidylinositol 3-kinase to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor I (IGF-I).
The report 'RAC Alpha SerineThreonine Protein Kinase - Pipeline Review, H2 2018' outlays comprehensive information on the RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 6, 2 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.
Report covers products from therapy areas Oncology, Hematological Disorders, Non Malignant Disorders and Other Diseases which include indications Endometrial Cancer, Metastatic Breast Cancer, Melanoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer, Hepatocellular Carcinoma, Prostate Cancer, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Small-Cell Lung Cancer, Solid Tumor, Anal Cancer, Fallopian Tube Cancer, Gastric Cancer, Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), Lymphoma, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Orphan Diseases (Rare Diseases), Pancreatic Cancer, Peritoneal Cancer, Proteus Syndrome, Renal Cell Carcinoma, Salivary Gland Cancer, Sickle Cell Disease and Thymoma (Thymic Epithelial Tumor).
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1)
- The report reviews RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Overview
RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
ArQule Inc
AstraZeneca Plc
Bayer AG
Merck & Co Inc
Merck KGaA
Novartis AG
Rexahn Pharmaceuticals Inc
RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Drug Profiles
ARQ-751 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1125976 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
capivasertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-2698 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
miransertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-2206 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-2206 + selumetinib sulfate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NISC-6 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RX-0201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RX-0201N - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit AKT1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trametinib dimethyl sulfoxide + uprosertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
uprosertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Dormant Products
RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Discontinued Products
RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Oct 19, 2018: ArQule presents orphan disease clinical data at the American Society of Human Genetics (ASHG) 2018 Annual Meeting for its pan-AKT inhibitor, Miransertib (ARQ 092)
Oct 04, 2018: ArQule to Present Clinical Update for Miransertib in Rare Disease at the American Society of Human Genetics 2018 Annual Meeting
Sep 13, 2018: Miransertib (ARQ 092) granted fast track designation for the treatment of PIK3CA-related overgrowth spectrum (PROS)
May 16, 2018: Merck to Present Poster on M2698 at ASCO 2018
Mar 15, 2018: ArQule to Present Data on miransertib at the 2018 American Association for Cancer Research (AACR) Annual Meeting
Mar 15, 2018: ArQule to Provide Update on ARQ
Nov 01, 2017: FDA Grants Rare Pediatric Disease Designation to ArQule's Miransertib (ARQ 092) for the Treatment of Proteus Syndrome
Aug 30, 2017: Merck To Present Data On M2698 At ESMO 2017
Jun 07, 2017: ArQule Announces First Patient Dosed in Company Sponsored Phase 1/2 Trial of AKT Inhibitor, ARQ 092, for Rare Overgrowth Diseases
May 17, 2017: ArQule to Present Clinical Data on ARQ-092 at the 2017 American Society of Clinical Oncology Annual Meeting
Dec 03, 2016: Preclinical Data on Proprietary AKT Inhibitor, ARQ 092, Demonstrating Effectiveness in the Treatment of Sickle Cell Disease Presented at the American Society of Hematology Annual Meeting
Jun 06, 2016: Rexahn Pharmaceuticals Presents Clinical Data on Archexin at the 2016 ASCO Annual Meeting
Apr 20, 2016: Rexahn Pharmaceuticals Presents Clinical Trial Results for Archexin at the 2016 American Association for Cancer Research Annual Meeting
Apr 20, 2016: Rexahn Pharmaceuticals Presents pre-Clinical Trial Data for Archexin-Nano at the 2016 American Association for Cancer Research Annual Meeting
Feb 08, 2016: Rexahn Pharmaceuticals Completes Stage 1 and Begins Enrollment in Stage 2 of Archexin Phase IIa Clinical Trial in Metastatic Renal Cell Carcinoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Overview
RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
ArQule Inc
AstraZeneca Plc
Bayer AG
Merck & Co Inc
Merck KGaA
Novartis AG
Rexahn Pharmaceuticals Inc
RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Drug Profiles
ARQ-751 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1125976 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
capivasertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-2698 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
miransertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-2206 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-2206 + selumetinib sulfate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NISC-6 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RX-0201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RX-0201N - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit AKT1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trametinib dimethyl sulfoxide + uprosertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
uprosertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Dormant Products
RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Discontinued Products
RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Oct 19, 2018: ArQule presents orphan disease clinical data at the American Society of Human Genetics (ASHG) 2018 Annual Meeting for its pan-AKT inhibitor, Miransertib (ARQ 092)
Oct 04, 2018: ArQule to Present Clinical Update for Miransertib in Rare Disease at the American Society of Human Genetics 2018 Annual Meeting
Sep 13, 2018: Miransertib (ARQ 092) granted fast track designation for the treatment of PIK3CA-related overgrowth spectrum (PROS)
May 16, 2018: Merck to Present Poster on M2698 at ASCO 2018
Mar 15, 2018: ArQule to Present Data on miransertib at the 2018 American Association for Cancer Research (AACR) Annual Meeting
Mar 15, 2018: ArQule to Provide Update on ARQ
Nov 01, 2017: FDA Grants Rare Pediatric Disease Designation to ArQule's Miransertib (ARQ 092) for the Treatment of Proteus Syndrome
Aug 30, 2017: Merck To Present Data On M2698 At ESMO 2017
Jun 07, 2017: ArQule Announces First Patient Dosed in Company Sponsored Phase 1/2 Trial of AKT Inhibitor, ARQ 092, for Rare Overgrowth Diseases
May 17, 2017: ArQule to Present Clinical Data on ARQ-092 at the 2017 American Society of Clinical Oncology Annual Meeting
Dec 03, 2016: Preclinical Data on Proprietary AKT Inhibitor, ARQ 092, Demonstrating Effectiveness in the Treatment of Sickle Cell Disease Presented at the American Society of Hematology Annual Meeting
Jun 06, 2016: Rexahn Pharmaceuticals Presents Clinical Data on Archexin at the 2016 ASCO Annual Meeting
Apr 20, 2016: Rexahn Pharmaceuticals Presents Clinical Trial Results for Archexin at the 2016 American Association for Cancer Research Annual Meeting
Apr 20, 2016: Rexahn Pharmaceuticals Presents pre-Clinical Trial Data for Archexin-Nano at the 2016 American Association for Cancer Research Annual Meeting
Feb 08, 2016: Rexahn Pharmaceuticals Completes Stage 1 and Begins Enrollment in Stage 2 of Archexin Phase IIa Clinical Trial in Metastatic Renal Cell Carcinoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by ArQule Inc, H2 2018
Pipeline by AstraZeneca Plc, H2 2018
Pipeline by Bayer AG, H2 2018
Pipeline by Merck & Co Inc, H2 2018
Pipeline by Merck KGaA, H2 2018
Pipeline by Novartis AG, H2 2018
Pipeline by Rexahn Pharmaceuticals Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Dormant Products, H2 2018 (Contd.2), H2 2018
Dormant Products, H2 2018 (Contd.3), H2 2018
Discontinued Products, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by ArQule Inc, H2 2018
Pipeline by AstraZeneca Plc, H2 2018
Pipeline by Bayer AG, H2 2018
Pipeline by Merck & Co Inc, H2 2018
Pipeline by Merck KGaA, H2 2018
Pipeline by Novartis AG, H2 2018
Pipeline by Rexahn Pharmaceuticals Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Dormant Products, H2 2018 (Contd.2), H2 2018
Dormant Products, H2 2018 (Contd.3), H2 2018
Discontinued Products, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
ArQule Inc
AstraZeneca Plc
Bayer AG
Merck & Co Inc
Merck KGaA
Novartis AG
Rexahn Pharmaceuticals Inc
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
ArQule Inc
AstraZeneca Plc
Bayer AG
Merck & Co Inc
Merck KGaA
Novartis AG
Rexahn Pharmaceuticals Inc
